DK1252157T3 - Pyrimidin-carboxamider anvendelige som inhibitorer af PDE4 isozymer - Google Patents

Pyrimidin-carboxamider anvendelige som inhibitorer af PDE4 isozymer

Info

Publication number
DK1252157T3
DK1252157T3 DK01901334T DK01901334T DK1252157T3 DK 1252157 T3 DK1252157 T3 DK 1252157T3 DK 01901334 T DK01901334 T DK 01901334T DK 01901334 T DK01901334 T DK 01901334T DK 1252157 T3 DK1252157 T3 DK 1252157T3
Authority
DK
Denmark
Prior art keywords
inhibitors
pde4 isozymes
carboxamides useful
pyrimidine carboxamides
pyrimidine
Prior art date
Application number
DK01901334T
Other languages
Danish (da)
English (en)
Inventor
Robert James Chambers
Thomas Victor Magee
Anthony Marfat
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1252157T3 publication Critical patent/DK1252157T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00ย -ย A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
DK01901334T 2000-01-31 2001-01-30 Pyrimidin-carboxamider anvendelige som inhibitorer af PDE4 isozymer DK1252157T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17928200P 2000-01-31 2000-01-31
EP01901334A EP1252157B1 (en) 2000-01-31 2001-01-30 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes

Publications (1)

Publication Number Publication Date
DK1252157T3 true DK1252157T3 (da) 2004-10-25

Family

ID=22655926

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01901334T DK1252157T3 (da) 2000-01-31 2001-01-30 Pyrimidin-carboxamider anvendelige som inhibitorer af PDE4 isozymer

Country Status (45)

Country Link
US (1) US6740655B2 (2)
EP (1) EP1252157B1 (2)
JP (1) JP2003522165A (2)
KR (1) KR20020071029A (2)
CN (1) CN1404480A (2)
AP (1) AP2002002590A0 (2)
AR (1) AR027336A1 (2)
AT (1) ATE269860T1 (2)
AU (1) AU2700301A (2)
BG (1) BG106868A (2)
BR (1) BR0107934A (2)
CA (1) CA2396458C (2)
CO (1) CO5271669A1 (2)
CR (1) CR6714A (2)
CZ (1) CZ20022413A3 (2)
DE (1) DE60103976T2 (2)
DK (1) DK1252157T3 (2)
DZ (1) DZ3406A1 (2)
EA (1) EA005028B1 (2)
EE (1) EE200200426A (2)
ES (1) ES2223772T3 (2)
GE (1) GEP20043385B (2)
GT (1) GT200100023A (2)
HK (1) HK1054232A1 (2)
HN (1) HN2001000018A (2)
HU (1) HUP0204271A3 (2)
IL (1) IL150486A0 (2)
IS (1) IS6444A (2)
MA (1) MA26871A1 (2)
MX (1) MXPA02007465A (2)
NO (1) NO20023614L (2)
NZ (1) NZ519726A (2)
OA (1) OA12170A (2)
PA (1) PA8511301A1 (2)
PE (1) PE20011059A1 (2)
PL (1) PL357555A1 (2)
PT (1) PT1252157E (2)
PY (1) PY0102108A (2)
SK (1) SK10342002A3 (2)
SV (1) SV2001000298A (2)
TN (1) TNSN01019A1 (2)
TR (1) TR200402292T4 (2)
UY (1) UY26570A1 (2)
WO (1) WO2001057025A1 (2)
ZA (1) ZA200206034B (2)

Families Citing this family (86)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2238334T3 (es) * 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10110772A1 (de) * 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
YU39503A (sh) * 2000-11-22 2006-05-25 F. Hoffmann-La Roche Ag. Derivati pirimidina
WO2002060898A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
IL156413A0 (en) 2001-01-31 2004-01-04 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
ATE305467T1 (de) * 2001-01-31 2005-10-15 Pfizer Prod Inc Als inhibitoren von pde4-isozymen geeignete etherderivate
ES2239203T3 (es) * 2001-01-31 2005-09-16 Pfizer Products Inc. Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4.
KR20040007596A (ko) * 2001-05-23 2004-01-24 ๋‹ค๋‚˜๋ฒ  ์„ธ์ด์•ผ๊พธ ๊ฐ€๋ถ€์‹œํ‚ค๊ฐ€์ด์ƒค ๊ณจ์ ˆ ์น˜๋ฃŒ ์ด‰์ง„์šฉ ์กฐ์„ฑ๋ฌผ
ES2427930T3 (es) * 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composiciรณn terapรฉutica para el tratamiento regenerativo de enfermedades de los cartรญlagos
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus รŸ-adrenergen Agonisten und NDMA-Antagonisten
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US6951869B2 (en) * 2002-02-26 2005-10-04 Schlesinger Stephen L Use of leukotriene receptor antagonist for treatment of scarring
ME00565A (en) * 2002-05-28 2011-12-20 Topically applicable pharmaceutical preparation
DE10224888A1 (de) * 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040001895A1 (en) * 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
EP2322243A1 (en) * 2002-08-29 2011-05-18 Cipla Ltd. Pharmaceutical products and compositions comprising formoterol, ciclesonide and tiotropium
WO2004022096A1 (en) * 2002-09-06 2004-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP1617888B1 (en) 2003-04-23 2019-06-12 Valeritas, Inc. Hydraulically actuated pump for long duration medicament administration
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US20050020587A1 (en) * 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
GB0317484D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317498D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Compounds
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
US7132435B2 (en) * 2003-07-25 2006-11-07 Pfizer Inc. Compounds
US20050059643A1 (en) * 2003-08-05 2005-03-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a steroid and a betamimetic
CA2534352A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
JP2007511539A (ja) * 2003-11-14 2007-05-10 ใƒใ‚ฏใ‚นใ‚ฟใƒผใƒปใ‚คใƒณใ‚ฟใƒผใƒŠใ‚ทใƒงใƒŠใƒซใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ฮฑ๏ผ‘โˆ’ๆŠ—ใƒˆใƒชใƒ—ใ‚ทใƒณ็ต„ๆˆ็‰ฉใŠใ‚ˆใณใ“ใฎใ‚ˆใ†ใช็ต„ๆˆ็‰ฉใ‚’็”จใ„ใŸๅ‡ฆ็ฝฎๆ–นๆณ•
WO2006073413A1 (en) * 2004-02-20 2006-07-13 The Board Of Trustees Of The University Of Illinois Blood pressure reduction in salt-sensitive
CA2559062A1 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
US20050239842A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006014425A1 (en) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
RU2279878C2 (ru) * 2004-08-17 2006-07-20 ะ“ะพััƒะดะฐั€ัั‚ะฒะตะฝะฝะพะต ะพะฑั€ะฐะทะพะฒะฐั‚ะตะปัŒะฝะพะต ัƒั‡ั€ะตะถะดะตะฝะธะต ะฒั‹ััˆะตะณะพ ะฟั€ะพั„ะตััะธะพะฝะฐะปัŒะฝะพะณะพ ะพะฑั€ะฐะทะพะฒะฐะฝะธั "ะ‘ะะจะšะ˜ะ ะกะšะ˜ะ™ ะ“ะžะกะฃะ”ะะ ะกะขะ’ะ•ะะะซะ™ ะœะ•ะ”ะ˜ะฆะ˜ะะกะšะ˜ะ™ ะฃะะ˜ะ’ะ•ะ ะกะ˜ะขะ•ะข ะคะตะดะตั€ะฐะปัŒะฝะพะณะพ ะะณะตะฝั‚ัั‚ะฒะฐ ะฟะพ ะทะดั€ะฐะฒะพะพั…ั€ะฐะฝะตะฝะธัŽ ะธ ัะพั†ะธะฐะปัŒะฝะพะผัƒ ั€ะฐะทะฒะธั‚ะธัŽ" (ะ“ะžะฃ ะ’ะŸะž ะ‘ะ“ะœะฃ ะ ะžะกะ—ะ”ะ ะะ’ะ) ะกะฟะพัะพะฑ ะทะฐั‰ะธั‚ั‹ ะณะพะปะพะฒะฝะพะณะพ ะผะพะทะณะฐ ะฒ ั€ะตะบะพะฝัั‚ั€ัƒะบั‚ะธะฒะฝะพะน ั…ะธั€ัƒั€ะณะธะธ ัะพะฝะฝั‹ั… ะฐั€ั‚ะตั€ะธะน
US7728143B2 (en) 2004-10-08 2010-06-01 Abbott Laboratories Salt and crystalline forms thereof of a drug
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
WO2006097547A1 (es) * 2005-03-17 2006-09-21 Proyecto De Biomedicina Cima S.L. Empleo de 5'-metiltioadenosina (mta) en la prevenciรณn y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CN103239773B (zh) 2006-03-30 2015-08-26 ็“ฆ่Žฑ้‡Œๅก”ๆ–ฏๅ…ฌๅธ ๅคš็ญ’ๅผๆตไฝ“้€’้€ๅ™จๆขฐ
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
WO2008088727A2 (en) * 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
GB0706398D0 (en) * 2007-04-02 2007-05-09 Univ Hospital Of North Staford Improvements in and relating to copd determination
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF ฮฑ plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US7989465B2 (en) * 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CN105367503A (zh) 2007-10-19 2016-03-02 ้˜ฟ็ปดๆ‹‰ๅˆถ่ฏๅ…ฌๅธ ๆ‚่ŠณๅŸบๅŒ–ๅˆ็‰ฉๅ’Œๅ…ถ็”จ้€”
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8138339B2 (en) * 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
AU2008359989A1 (en) * 2008-07-30 2010-02-04 Nitto Denko Corporation Drug carriers
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
WO2012133492A1 (ja) * 2011-03-31 2012-10-04 ใƒžใƒซใƒ›ๆ ชๅผไผš็คพ ่ฃฝๅ‰คๅฎ‰ๅฎšๆ€งใซๅ„ชใ‚ŒใŸ่ปŸ่†ๅ‰ค
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102850321A (zh) * 2011-06-28 2013-01-02 ไธญๅ›ฝ็ง‘ๅญฆ้™ขไธŠๆตท่ฏ็‰ฉ็ ”็ฉถๆ‰€ ่Šณ้ฆ™ๆฐงๅŸบๅ˜งๅ•ถ็”ฒ้…ฐ่ƒบๆˆ–่Šณ้ฆ™ๆฐงๅŸบๅกๅ•ถ็”ฒ้…ฐ่ƒบ็ฑปๅŒ–ๅˆ็‰ฉๅŠๅ…ถๅˆถๅค‡ๆ–นๆณ•ใ€่ฏ็‰ฉ็ป„ๅˆ็‰ฉๅ’Œ็”จ้€”
CA3094793A1 (en) 2011-11-23 2013-05-30 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
KR102006547B1 (ko) * 2017-11-16 2019-08-01 ์„œ์šธ๋Œ€ํ•™๊ต์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ๋ฒค์ฆˆ์•„๋ฏธ๋“œ ์œ ๋„์ฒด ํ™”ํ•ฉ๋ฌผ, ์ด์˜ ์ œ์กฐ๋ฐฉ๋ฒ• ๋ฐ ์ด๋ฅผ ์œ ํšจ์„ฑ๋ถ„์œผ๋กœ ํ•จ์œ ํ•˜๋Š” ์—ผ์ฆ์งˆํ™˜์˜ ์น˜๋ฃŒ ๋˜๋Š” ์˜ˆ๋ฐฉ์šฉ ์•ฝํ•™์  ์กฐ์„ฑ๋ฌผ
WO2019139479A1 (en) * 2018-01-11 2019-07-18 Rob Janssen Compositions and methods for the treatment of lung emphysema and other forms of copd
KR102200032B1 (ko) * 2019-03-13 2021-01-08 ์ „๋‚จ๋Œ€ํ•™๊ต์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ํ˜ธํก๊ธฐ ์งˆํ™˜์˜ ์˜ˆ๋ฐฉ ๋˜๋Š” ์น˜๋ฃŒ์šฉ ์กฐ์„ฑ๋ฌผ
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (4)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4861891A (en) * 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
TW429148B (en) * 1995-10-27 2001-04-11 Pfizer Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
NZ337698A (en) 1997-04-04 2001-07-27 Pfizer Prod Inc Nicotinamide derivatives for selective inhibition of phosphodiesterase type 4 (PDE4) and the production of tumour necrosis factor (TNF) useful for the treatment of respiratory, rheumatoid and allergic diseases
YU39503A (sh) * 2000-11-22 2006-05-25 F. Hoffmann-La Roche Ag. Derivati pirimidina

Also Published As

Publication number Publication date
GT200100023A (es) 2001-12-19
AP2002002590A0 (en) 2002-09-30
SV2001000298A (es) 2001-07-03
GEP20043385B (en) 2004-04-13
NO20023614D0 (no) 2002-07-30
HUP0204271A3 (en) 2003-07-28
CN1404480A (zh) 2003-03-19
EA005028B1 (ru) 2004-10-28
KR20020071029A (ko) 2002-09-11
HK1054232A1 (zh) 2003-11-21
PA8511301A1 (es) 2002-12-11
CR6714A (es) 2004-01-14
DE60103976D1 (de) 2004-07-29
ATE269860T1 (de) 2004-07-15
AU2700301A (en) 2001-08-14
PT1252157E (pt) 2004-10-29
HN2001000018A (es) 2001-09-11
DZ3406A1 (2) 2001-08-09
CA2396458C (en) 2006-12-05
EP1252157A1 (en) 2002-10-30
SK10342002A3 (sk) 2003-12-02
ES2223772T3 (es) 2005-03-01
NO20023614L (no) 2002-09-30
PL357555A1 (en) 2004-07-26
ZA200206034B (en) 2003-07-29
JP2003522165A (ja) 2003-07-22
PY0102108A (es) 2003-10-01
AR027336A1 (es) 2003-03-26
US6740655B2 (en) 2004-05-25
DE60103976T2 (de) 2005-07-21
TNSN01019A1 (fr) 2005-11-10
BR0107934A (pt) 2003-03-25
CO5271669A1 (es) 2003-04-30
CA2396458A1 (en) 2001-08-09
IS6444A (is) 2002-06-25
MXPA02007465A (es) 2002-12-13
UY26570A1 (es) 2001-08-27
IL150486A0 (en) 2002-12-01
HUP0204271A2 (en) 2003-05-28
EE200200426A (et) 2003-12-15
EA200200739A1 (ru) 2002-12-26
EP1252157B1 (en) 2004-06-23
CZ20022413A3 (cs) 2003-08-13
PE20011059A1 (es) 2001-10-19
TR200402292T4 (tr) 2004-12-21
NZ519726A (en) 2004-05-28
BG106868A (bg) 2003-01-31
US20030144300A1 (en) 2003-07-31
WO2001057025A1 (en) 2001-08-09
OA12170A (en) 2006-05-08
MA26871A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
DK1252157T3 (da) Pyrimidin-carboxamider anvendelige som inhibitorer af PDE4 isozymer
NO20033399D0 (no) Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer
NO20033397D0 (no) Nikotinamidbiarylderivater nyttige som inhibitorer av PDE4 isozymer
NO20023613D0 (no) Nikotinamid benzokondenserte heterocyclyl derivater nyttige som selektive inhibitorer av PDE4 isozymer
DK1463506T3 (da) Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser
DK1532138T3 (da) Inhibitorer af tyrosinkinaser
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
DK1443925T3 (da) Naphthyridinderivater, deres fremstilling og deres anvendelse som inhibitorer af phosphodiesteraseisoenzym 4 (PDE4)
DK1330452T3 (da) Pyrazinderivater som modulatorer af tyrosinkinaser
DK1307263T3 (da) Hidtil ukendt anvendelse af lipaseinhibitorer
DK1276738T3 (da) 2-amino-3- (alkyl) - pyrimidinderivater som GSK3-betainhibitorer
NO20033593D0 (no) Kinazoliner som MMP-13 inhibitorer
DK1183033T3 (da) Pyrrolotriazininhibitorer af kinaser
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
NO20024997D0 (no) 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer
NO20033288L (no) Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer
NO20025811D0 (no) Forbindelser som er effektive som beta-2-adrenoreseptor- anonister sรฅ vel som PDE4-inhibitorer
DK1401828T3 (da) N-Formylhydroxylaminforbindelser som inhibitorer af PDF
NO20021959L (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20035206L (no) Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer
DK1252158T3 (da) Benzo-annelleret heterocyclyl-nicotinamed-derivater, der er nyttige som selektive inhibitorer af PDE4-isozymer
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer
SE0004239D0 (sv) New use of an inhibitor